Evaxion begins experimental testing of two AI-Immunology autoimmune treatment concepts
EVAX•Programs target underlying disease drivers
The programs aim to target underlying disease drivers, seeking improved efficacy with fewer side effects than current symptom-focused therapies.
AI-Immunology expands into autoimmune disease
Evaxion expanded its AI-Immunology platform into autoimmune diseases, testing two new treatment concepts in experimental studies.
Initial results have not been presented yet; the company plans to present experimental data on November 18, 2026 at PEGS Europe.
Management sees strategic expansion potential
Management framed the move as a strategic expansion into a high unmet-need area with partnership potential across drug development stages.
